Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa

Joslyn S. Kirby; Linnea Thorlacius; Jérémy Lambert; Valerie Ciaravino; Robert Rolleri; Ingrid Pansar; Edward Muller; Christopher G. Pelligra; John R. Ingram

doi:10.1093/bjd/ljaf067

Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL^©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa

Joslyn S. Kirby
, Linnea Thorlacius
, Jérémy Lambert
, Valerie Ciaravino
, Robert Rolleri
, Ingrid Pansar
, Edward Muller
, Christopher G. Pelligra
, John R. Ingram

Department of Dermatology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Background Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition which negatively impacts patients' physical and mental wellbeing.

Original language	English (US)
Pages (from-to)	93-104
Number of pages	12
Journal	British Journal of Dermatology
Volume	193
Issue number	1
DOIs	https://doi.org/10.1093/bjd/ljaf067
State	Published - Jul 1 2025

All Science Journal Classification (ASJC) codes

Dermatology

Access to Document

10.1093/bjd/ljaf067

Fingerprint

Dive into the research topics of 'Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL^©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa'. Together they form a unique fingerprint.

Cite this

Kirby, J. S., Thorlacius, L., Lambert, J., Ciaravino, V., Rolleri, R., Pansar, I., Muller, E., Pelligra, C. G., & Ingram, J. R. (2025). Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL^©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. British Journal of Dermatology, 193(1), 93-104. https://doi.org/10.1093/bjd/ljaf067

@article{a5172fda83f041c5885162639c718378,

title = "Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL{\textcopyright}) questionnaire using pooled data from the phase III BE HEARD I \& II trials of bimekizumab in hidradenitis suppurativa",

abstract = "Background Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition which negatively impacts patients' physical and mental wellbeing.",

author = "Kirby, \{Joslyn S.\} and Linnea Thorlacius and J{\'e}r{\'e}my Lambert and Valerie Ciaravino and Robert Rolleri and Ingrid Pansar and Edward Muller and Pelligra, \{Christopher G.\} and Ingram, \{John R.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = jul,

day = "1",

doi = "10.1093/bjd/ljaf067",

language = "English (US)",

volume = "193",

pages = "93--104",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Oxford University Press",

number = "1",

}

Kirby, JS, Thorlacius, L, Lambert, J, Ciaravino, V, Rolleri, R, Pansar, I, Muller, E, Pelligra, CG & Ingram, JR 2025, 'Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL^©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa', British Journal of Dermatology, vol. 193, no. 1, pp. 93-104. https://doi.org/10.1093/bjd/ljaf067

Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL^©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. / Kirby, Joslyn S.; Thorlacius, Linnea; Lambert, Jérémy et al.
In: British Journal of Dermatology, Vol. 193, No. 1, 01.07.2025, p. 93-104.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa

AU - Kirby, Joslyn S.

AU - Thorlacius, Linnea

AU - Lambert, Jérémy

AU - Ciaravino, Valerie

AU - Rolleri, Robert

AU - Pansar, Ingrid

AU - Muller, Edward

AU - Pelligra, Christopher G.

AU - Ingram, John R.

PY - 2025/7/1

Y1 - 2025/7/1

N2 - Background Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition which negatively impacts patients' physical and mental wellbeing.

AB - Background Hidradenitis suppurativa (HS) is a chronic, inflammatory skin condition which negatively impacts patients' physical and mental wellbeing.

UR - https://www.scopus.com/pages/publications/105008977439

UR - https://www.scopus.com/pages/publications/105008977439#tab=citedBy

U2 - 10.1093/bjd/ljaf067

DO - 10.1093/bjd/ljaf067

M3 - Article

C2 - 40172122

AN - SCOPUS:105008977439

SN - 0007-0963

VL - 193

SP - 93

EP - 104

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 1

ER -

Kirby JS, Thorlacius L, Lambert J, Ciaravino V, Rolleri R, Pansar I et al. Psychometric validation and interpretation thresholds of the Hidradenitis Suppurativa Quality of Life (HiSQOL^©) questionnaire using pooled data from the phase III BE HEARD I & II trials of bimekizumab in hidradenitis suppurativa. British Journal of Dermatology. 2025 Jul 1;193(1):93-104. doi: 10.1093/bjd/ljaf067